Company Overview
About Barricaid
Barricaid is the commercial brand name for the Barricaid Annular Closure Device (ACD), a medical device developed and marketed by Intrinsic Therapeutics, a clinical-stage medical device company. The Barricaid ACD received FDA premarket approval on February 8, 2019. It is designed to treat lumbar disc herniation by sealing tears in the annulus fibrosus — the tough outer layer of spinal discs — following discectomy (the surgical removal of herniated disc material). By closing the annular defect, Barricaid aims to contain remaining disc material, reduce the likelihood of reherniation, and alleviate nerve compression and back pain.
Business Model & Competitive Advantage
The Barricaid device has been implanted in more than 12,000 patients globally and is supported by extensive clinical evidence across 8 distinct patient populations, including two randomized controlled trials and six single-arm studies. In 2025, the Centers for Medicare & Medicaid Services (CMS) significantly improved Barricaid's reimbursement: the ASC payment rate increased 46% from $6,500 to $9,527, substantially improving the economics for outpatient surgical centers. ISASS (International Society for the Advancement of Spine Surgery) also issued updated 2025 recommendations affirming Barricaid's medical necessity for high-risk discectomy patients with large annular defects.
Competitive Landscape 2025–2026
2025 was a landmark year for Barricaid's clinical advancement: the device was successfully implanted for the first time via an endoscopic (minimally invasive) approach, and separately implanted for the first time in patients under awake sedation (without general anesthesia). These minimally invasive technique expansions are expected to broaden the treatable patient population and increase adoption at outpatient surgery centers. Barricaid competes with Xclose and Inclose as the primary annular closure devices on the market, with Barricaid holding the strongest clinical evidence base.
Key Differentiators
Strong Challenger
Barricaid is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Similar Brands
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
PointClickCare
PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the compan
CoverMyMeds
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline t
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Compare Barricaid with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Barricaid? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Barricaid Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Barricaid vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →